In SLE thrombocytopenia is mainly related to anti-platelet antibodies and antiphospholipid antibodies, while infections and medications need to be excluded. there are two types of thrombocytopenia caused by SLE, one decreases with SLE activity and improves with treatment remission, and the other maintains a platelet count of about 5×10^9/L without severe bleeding and no signs of lupus activity in other organs. For the case you mentioned, I think we also need to analyze it in combination with previous platelet levels. If there is a significant and rapid recent decrease, for example, 100-61×10^9/L, accompanied by progressive hypocomplementemia and elevated ds-DNA titers, as well as manifestations of multisystem damage such as fever, rash, arthritis, plasma membrane inflammation, oral ulcers, hair loss, urine protein, headache, and reduced white blood cells, we need to Consider SLE due to the activity of this disease, when intensive immunosuppressive therapy, such as hormone dosing or shock therapy, is needed. If severe cases are accompanied by a tendency to bleed from the gums, skin mucosa or internal organs, immunoglobulin shock therapy can be applied if necessary. If the current platelet level is similar to the previous level, with only small fluctuations (68-61×10^9/L), and is not accompanied by significant manifestations of multisystem damage and bleeding tendency, it may not necessarily be due to SEL activity, but may be related to infection and adverse drug reactions, at which time the influencing factors need to be removed and changes in platelet levels need to be observed, and intensive immunosuppressive therapy is not required for the time being. In conclusion, the platelet level, bleeding tendency and multisystem damage should be closely monitored to identify whether the reduced platelet level is caused by the activity of SLE and to treat them differently.